Aggregation-Inhibiting scFv-Based Therapies Protect Mice against AAV1/2-Induced A53T-α-Synuclein Overexpression.

Biomolecules · 2023 · PMC10452369 · PMID 37627268

Europe PMC DOI

hedged sentence

0.0950

closest p · 1.9× alpha

0.0950

boldest claim

The sentences

approached significancep = 0.095so close (0.05 < p ≤ 0.1)

There were no significant differences observed, except in the case of AAV and NP-encapsulated scFv treatments, which approached significance at 10 weeks ( p = 0.095).

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.